Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22290559 | 0.82 | KDM4E (0.41) | KDM4E | |
| SCHEMBL22290701 | 0.81 | GABRG2 (0.34) | — | |
| Hydrochloric Acid SCHEMBL25258396 | 0.80 | KDM4E (0.41) | KDM4E | |
| SCHEMBL24035868 | 0.75 | KDM4E (0.37) | KDM4E | |
| SCHEMBL22134229 | 0.74 | KDM4E (0.38) | KDM4E | |
| SCHEMBL2664184 | 0.73 | KDM4E (0.42) | KDM4E | |
| SCHEMBL23705567 | 0.70 | PLA2G4A (0.37) | KDM4E | |
| SCHEMBL23705527 | 0.69 | ALDH1A1 (0.36) | KDM4E | |
| SCHEMBL670904 | 0.69 | CYP11B1 (0.43) | KDM4E | |
| SCHEMBL170374 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3917527-B1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-113645971-B | Compounds and uses thereof | 福宏治疗公司 | 2024-10-18 | — | — | CN | disclosed |
| US-20230121497-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-03-16 | — | — | US | disclosed |
| EP-4096668-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-3917527-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2021-12-08 | — | — | EP | disclosed |
| CN-113645971-A | Compound and use thereof | 福宏治疗公司 | 2021-11-12 | — | — | CN | disclosed |
| WO-2021155264-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155264-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160180-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2020-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079819-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | KDM4E 1848/4885 |
| US-20230121497-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | KDM4E 1848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.